Ultragenyx is trading at $26.79 (+4.14%) after the August 19 FDA approval of GENGLYCOS, its first approved gene therapy.

  • Reuters reported the announcement sent shares 7.5% higher after-hours.
  • Canaccord raised its price target to $83 and maintained Buy; H.C. Wainwright reiterated Buy at $50.
  • Biotech’s 2.06% advance and broader risk-on sentiment add sector support.